MHRA Approves Lurbinectedin for Small Cell Lung Cancer Maintenance Treatment
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved lurbinectedin, marketed as Zepzelca, as a maintenance treatment for adults with extensive-stage small cell lung cancer (SCLC) whose disease has ... Read More